Article Versions Notes

Dahlsson Leitao C, S. Rinne S, Altai M, Vorontsova O, Dunås F, Jonasson P, Tolmachev V, Löfblom J, Ståhl S, Orlova A. Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. Pharmaceutics. 2020; 12(6):551. https://doi.org/10.3390/pharmaceutics12060551

Dahlsson Leitao, Charles, Sara S. Rinne, Mohamed Altai, Olga Vorontsova, Finn Dunås, Per Jonasson, Vladimir Tolmachev, John Löfblom, Stefan Ståhl, and Anna Orlova. 2020. "Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model" Pharmaceutics 12, no. 6: 551. https://doi.org/10.3390/pharmaceutics12060551

Dahlsson Leitao, C., S. Rinne, S., Altai, M., Vorontsova, O., Dunås, F., Jonasson, P., Tolmachev, V., Löfblom, J., Ståhl, S., & Orlova, A. (2020). Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model. Pharmaceutics, 12(6), 551. https://doi.org/10.3390/pharmaceutics12060551